SCNX Q1 Revenue Soars 449%, EPS Loss Narrows to $0.08, Beating Estimates
SCNX sits 69% above its 52-week low of $0.238 on light trading volume (0.1× avg).
Summary
Scienture Holdings reported first-quarter 2026 results, with revenue surging 449% year-over-year to $56.33K and a diluted loss per share narrowing to $(0.08). This significantly beats analyst expectations of a $(0.22) loss per share, as reported just last week. The positive revenue growth, driven by the initial wholesale ramp of SCN-102 (ARBLI™), provides a much-needed positive data point following a series of recent negative developments, including new restrictive debt financing, alleged misrepresentation of debt, and a critical financial outlook with projected zero revenue for Q4'25. While the company's net loss widened to $(3.40M), the substantial revenue increase and better-than-expected EPS could offer some relief and suggest early traction in its strategic pivot to specialty pharma. Traders will be watching if this momentum can be sustained and if the company can improve its overall profitability and financial stability.
At the time of this announcement, SCNX was trading at $0.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.